Amylyx Pharmaceuticals announced that its current cash reserves are expected to be sufficient to support the company's operations, not only covering the potential commercialization process of the new drug Avexitide, but also sustaining operations through 2028.

Jefferies Financial Group Inc. recently responded to a lawsuit against the company, clearly stating that it believes the lawsuit is groundless and pledging to take strong legal action in its defense.

Ondas Holdings Inc. recently announced that it has received a new round of counter-drone system purchase orders from existing customers in the Middle East and other regions, with a total contract value of up to $6 million.

Servier and Day One Biopharmaceuticals Inc. jointly announced an acquisition agreement, which will significantly enhance Servier's product pipeline in the field of rare tumor treatments.

Zhiding Technology Co., Ltd. announced today that it has successfully regained compliance with the minimum share price requirement of the Nasdaq Capital Market.